# Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Source: https://onco.cc/trials/nct03164616/  
OnCo record `nct03164616` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Tremelimumab, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). is a phase 3 interventional study registered as NCT03164616 by AstraZeneca, with 1186 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2021-03-12. Interventions recorded: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin. Conditions listed: Non Small Cell Lung Cancer NSCLC. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: POSEIDON
- Tags: ctgov-ingest
- Registry id: NCT03164616
- Phase: 3
- Setting: A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
- Sponsor: AstraZeneca
- Enrolled: 1186
- Result: Durvalumab with chemotherapy improved progression-free survival (5.5 against 4.8 months, hazard ratio 0.74, p=0.0009) but not significantly overall survival; adding a limited course of tremelimumab improved both (overall survival 14.0 against 11.7 months, hazard ratio 0.77, p=0.0030).
- Outcomes: Progression-Free Survival (PFS); D + SoC Compared With SoC Alone: D + SoC 5.5 months vs SoC Alone 4.8 months, HR 0.74; Overall Survival (OS); D + SoC Compared With SoC Alone: D + SoC 13.3 months vs SoC Alone 11.7 months, HR 0.86; Objective Response Rate (ORR): T + D + SoC 46.3% vs D + SoC 48.5% vs SoC Alone 33.4%

## Notes

- POSEIDON randomised 1,013 patients with EGFR and ALK wild-type metastatic non-small-cell lung cancer 1:1:1 to tremelimumab 75 mg with durvalumab 1,500 mg and platinum chemotherapy for up to four 21-day cycles then durvalumab every four weeks with one further tremelimumab dose; to durvalumab with chemotherapy then durvalumab; or to chemotherapy alone for up to six cycles. Progression-free survival for durvalumab with chemotherapy against chemotherapy was 5.5 against 4.8 months (hazard ratio 0.74, 95 percent confidence interval 0.62 to 0.89, p=0.0009) and overall survival 13.3 against 11.7 months (0.86, 0.72 to 1.02, p=0.0758, not significant). Adding tremelimumab gave progression-free survival 6.2 against 4.8 months (0.72, 0.60 to 0.86, p=0.0003) and overall survival 14.0 against 11.7 months (0.77, 0.65 to 0.92, p=0.0030), with 24-month overall survival 32.9 against 22.1 percent. Maximum grade 3 or 4 treatment-related events occurred in 51.8, 44.6 and 44.4 percent respectively (Journal of Clinical Oncology 2023). There is no NICE recommendation for either POSEIDON regimen.

## Sources

- ClinicalTrials.gov NCT03164616: https://clinicaltrials.gov/study/NCT03164616
- POSEIDON (Journal of Clinical Oncology 2023): https://doi.org/10.1200/JCO.22.00975

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [CheckMate 227](https://onco.cc/trials/checkmate-227/), [CheckMate 9LA](https://onco.cc/trials/checkmate-9la/), [Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct02453282/), [Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)](https://onco.cc/trials/nct02542293/)

---
JSON: https://onco.cc/api/v1/entities/nct03164616.json